Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.
- DOI
- 10.1007/s40257-025-00975-3
- Published
- 2025 Nov
- Container
- American journal of clinical dermatology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40257-025-00975-3,
title = {Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.},
author = {Irvine AD and Prajapati VH and Guttman-Yassky E and Simpson EL and Papp KA and Blauvelt A and Chu CY and Hong HC and Gold LFS and de Bruin-Weller M and Bieber T and Kabashima K and Rosmarin D and Sancho C and Calimlim BM and Grada A and Yang Y and Wu X and Levy G and Raymundo EM and Teixeira HD and Silverberg JI},
year = {2025},
journal = {American journal of clinical dermatology},
doi = {10.1007/s40257-025-00975-3},
url = {https://doi.org/10.1007/s40257-025-00975-3}
}RIS
TY - JOUR TI - Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. AU - Irvine AD AU - Prajapati VH AU - Guttman-Yassky E AU - Simpson EL AU - Papp KA AU - Blauvelt A AU - Chu CY AU - Hong HC AU - Gold LFS AU - de Bruin-Weller M AU - Bieber T AU - Kabashima K AU - Rosmarin D AU - Sancho C AU - Calimlim BM AU - Grada A AU - Yang Y AU - Wu X AU - Levy G AU - Raymundo EM AU - Teixeira HD AU - Silverberg JI PY - 2025 JO - American journal of clinical dermatology DO - 10.1007/s40257-025-00975-3 UR - https://doi.org/10.1007/s40257-025-00975-3 ER -
APA
AD, I., VH, P., E, G., EL, S., KA, P., A, B., CY, C., HC, H., LFS, G., M, D. B., T, B., K, K., D, R., C, S., BM, C., A, G., Y, Y., X, W., G, L., EM, R., HD, T., & JI, S. (2025). Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.. American journal of clinical dermatology. https://doi.org/10.1007/s40257-025-00975-3
Source records
- pubmed · retrieved 2026-09-26T07:51:18.085Z